aluates Reports

$ 0.0

Automative

Global Kidney Cancer Medicine Market Research Report 2025

Published Date: July 2025

Report Code: QYRE-Auto-2Z6269

Global Kidney Cancer Medicine Market Insights Forecast to 2028

BUY CHAPTERS

Global Kidney Cancer Medicine Market Research Report 2025

Code: QYRE-Auto-2Z6269

Report

July 2025

Pages:92

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Pfizer Inc

Bristol–Myers Squibb

Roche

GSK

Novartis

Bayer

Merck

Exelixis Inc

Takeda

Eisai Co Ltd

CTTQ

AVEO Oncology

Everest Pharm

Cipla Ltd

NATco

Beacon Pharma

SAMARTH

Kidney Cancer Medicine Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Kidney Cancer Medicine Market

The global market for Kidney Cancer Medicine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Kidney cancer -- also called renal cancer -- is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Almost all kidney cancers first appear in the lining of tiny tubes (tubules) in the kidney. This type of kidney cancer is called renal cell carcinoma.

Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Medicine.

The Kidney Cancer Medicine market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Kidney Cancer Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Kidney Cancer Medicine companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Kidney Cancer Medicine Market Report

Report Metric	Details
Report Name	Kidney Cancer Medicine Market
CAGR	5%
Segment by Type	Monoclonal Antibody mTOR Inhibitors Kinase Inhibitors Other
Segment by Application	Renal Cell Carcinoma (RCC) Transitional Cell Carcinoma (TCC)
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis, Takeda, Eisai, CTTQ, AVEO Oncology, Everest Pharm, Cipla, NATCO, Beacon Pharma, SAMARTH
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer Medicine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Kidney Cancer Medicine Market report?

Ans: The main players in the Kidney Cancer Medicine Market are Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis, Takeda, Eisai, CTTQ, AVEO Oncology, Everest Pharm, Cipla, NATCO, Beacon Pharma, SAMARTH

What are the Application segmentation covered in the Kidney Cancer Medicine Market report?

Ans: The Applications covered in the Kidney Cancer Medicine Market report are Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC)

What are the Type segmentation covered in the Kidney Cancer Medicine Market report?

Ans: The Types covered in the Kidney Cancer Medicine Market report are Monoclonal Antibody, mTOR Inhibitors, Kinase Inhibitors, Other

Recommended Reports

Kidney & Renal Diseases

Cancer Drug Markets

Urological Cancer Therapies

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Kidney Cancer Medicine Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Monoclonal Antibody

1.2.3 mTOR Inhibitors

1.2.4 Kinase Inhibitors

1.2.5 Other

1.3 Market by Application

1.3.1 Global Kidney Cancer Medicine Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Renal Cell Carcinoma (RCC)

1.3.3 Transitional Cell Carcinoma (TCC)

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Kidney Cancer Medicine Market Perspective (2020-2031)

2.2 Global Kidney Cancer Medicine Growth Trends by Region

2.2.1 Global Kidney Cancer Medicine Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Kidney Cancer Medicine Historic Market Size by Region (2020-2025)

2.2.3 Kidney Cancer Medicine Forecasted Market Size by Region (2026-2031)

2.3 Kidney Cancer Medicine Market Dynamics

2.3.1 Kidney Cancer Medicine Industry Trends

2.3.2 Kidney Cancer Medicine Market Drivers

2.3.3 Kidney Cancer Medicine Market Challenges

2.3.4 Kidney Cancer Medicine Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Kidney Cancer Medicine Players by Revenue

3.1.1 Global Top Kidney Cancer Medicine Players by Revenue (2020-2025)

3.1.2 Global Kidney Cancer Medicine Revenue Market Share by Players (2020-2025)

3.2 Global Kidney Cancer Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Kidney Cancer Medicine Revenue

3.4 Global Kidney Cancer Medicine Market Concentration Ratio

3.4.1 Global Kidney Cancer Medicine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer Medicine Revenue in 2024

3.5 Global Key Players of Kidney Cancer Medicine Head office and Area Served

3.6 Global Key Players of Kidney Cancer Medicine, Product and Application

3.7 Global Key Players of Kidney Cancer Medicine, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Kidney Cancer Medicine Breakdown Data by Type

4.1 Global Kidney Cancer Medicine Historic Market Size by Type (2020-2025)

4.2 Global Kidney Cancer Medicine Forecasted Market Size by Type (2026-2031)

5 Kidney Cancer Medicine Breakdown Data by Application

5.1 Global Kidney Cancer Medicine Historic Market Size by Application (2020-2025)

5.2 Global Kidney Cancer Medicine Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Kidney Cancer Medicine Market Size (2020-2031)

6.2 North America Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Kidney Cancer Medicine Market Size by Country (2020-2025)

6.4 North America Kidney Cancer Medicine Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Kidney Cancer Medicine Market Size (2020-2031)

7.2 Europe Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Kidney Cancer Medicine Market Size by Country (2020-2025)

7.4 Europe Kidney Cancer Medicine Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Kidney Cancer Medicine Market Size (2020-2031)

8.2 Asia-Pacific Kidney Cancer Medicine Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Kidney Cancer Medicine Market Size by Region (2020-2025)

8.4 Asia-Pacific Kidney Cancer Medicine Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Kidney Cancer Medicine Market Size (2020-2031)

9.2 Latin America Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Kidney Cancer Medicine Market Size by Country (2020-2025)

9.4 Latin America Kidney Cancer Medicine Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Kidney Cancer Medicine Market Size (2020-2031)

10.2 Middle East & Africa Kidney Cancer Medicine Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Kidney Cancer Medicine Market Size by Country (2020-2025)

10.4 Middle East & Africa Kidney Cancer Medicine Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Kidney Cancer Medicine Introduction

11.1.4 Pfizer Revenue in Kidney Cancer Medicine Business (2020-2025)

11.1.5 Pfizer Recent Development

11.2 Bristol-Myers Squibb

11.2.1 Bristol-Myers Squibb Company Details

11.2.2 Bristol-Myers Squibb Business Overview

11.2.3 Bristol-Myers Squibb Kidney Cancer Medicine Introduction

11.2.4 Bristol-Myers Squibb Revenue in Kidney Cancer Medicine Business (2020-2025)

11.2.5 Bristol-Myers Squibb Recent Development

11.3 Roche

11.3.1 Roche Company Details

11.3.2 Roche Business Overview

11.3.3 Roche Kidney Cancer Medicine Introduction

11.3.4 Roche Revenue in Kidney Cancer Medicine Business (2020-2025)

11.3.5 Roche Recent Development

11.4 GSK

11.4.1 GSK Company Details

11.4.2 GSK Business Overview

11.4.3 GSK Kidney Cancer Medicine Introduction

11.4.4 GSK Revenue in Kidney Cancer Medicine Business (2020-2025)

11.4.5 GSK Recent Development

11.5 Novartis

11.5.1 Novartis Company Details

11.5.2 Novartis Business Overview

11.5.3 Novartis Kidney Cancer Medicine Introduction

11.5.4 Novartis Revenue in Kidney Cancer Medicine Business (2020-2025)

11.5.5 Novartis Recent Development

11.6 Bayer

11.6.1 Bayer Company Details

11.6.2 Bayer Business Overview

11.6.3 Bayer Kidney Cancer Medicine Introduction

11.6.4 Bayer Revenue in Kidney Cancer Medicine Business (2020-2025)

11.6.5 Bayer Recent Development

11.7 Merck & Co.

11.7.1 Merck & Co. Company Details

11.7.2 Merck & Co. Business Overview

11.7.3 Merck & Co. Kidney Cancer Medicine Introduction

11.7.4 Merck & Co. Revenue in Kidney Cancer Medicine Business (2020-2025)

11.7.5 Merck & Co. Recent Development

11.8 Exelixis

11.8.1 Exelixis Company Details

11.8.2 Exelixis Business Overview

11.8.3 Exelixis Kidney Cancer Medicine Introduction

11.8.4 Exelixis Revenue in Kidney Cancer Medicine Business (2020-2025)

11.8.5 Exelixis Recent Development

11.9 Takeda

11.9.1 Takeda Company Details

11.9.2 Takeda Business Overview

11.9.3 Takeda Kidney Cancer Medicine Introduction

11.9.4 Takeda Revenue in Kidney Cancer Medicine Business (2020-2025)

11.9.5 Takeda Recent Development

11.10 Eisai

11.10.1 Eisai Company Details

11.10.2 Eisai Business Overview

11.10.3 Eisai Kidney Cancer Medicine Introduction

11.10.4 Eisai Revenue in Kidney Cancer Medicine Business (2020-2025)

11.10.5 Eisai Recent Development

11.11 CTTQ

11.11.1 CTTQ Company Details

11.11.2 CTTQ Business Overview

11.11.3 CTTQ Kidney Cancer Medicine Introduction

11.11.4 CTTQ Revenue in Kidney Cancer Medicine Business (2020-2025)

11.11.5 CTTQ Recent Development

11.12 AVEO Oncology

11.12.1 AVEO Oncology Company Details

11.12.2 AVEO Oncology Business Overview

11.12.3 AVEO Oncology Kidney Cancer Medicine Introduction

11.12.4 AVEO Oncology Revenue in Kidney Cancer Medicine Business (2020-2025)

11.12.5 AVEO Oncology Recent Development

11.13 Everest Pharm

11.13.1 Everest Pharm Company Details

11.13.2 Everest Pharm Business Overview

11.13.3 Everest Pharm Kidney Cancer Medicine Introduction

11.13.4 Everest Pharm Revenue in Kidney Cancer Medicine Business (2020-2025)

11.13.5 Everest Pharm Recent Development

11.14 Cipla

11.14.1 Cipla Company Details

11.14.2 Cipla Business Overview

11.14.3 Cipla Kidney Cancer Medicine Introduction

11.14.4 Cipla Revenue in Kidney Cancer Medicine Business (2020-2025)

11.14.5 Cipla Recent Development

11.15 NATCO

11.15.1 NATCO Company Details

11.15.2 NATCO Business Overview

11.15.3 NATCO Kidney Cancer Medicine Introduction

11.15.4 NATCO Revenue in Kidney Cancer Medicine Business (2020-2025)

11.15.5 NATCO Recent Development

11.16 Beacon Pharma

11.16.1 Beacon Pharma Company Details

11.16.2 Beacon Pharma Business Overview

11.16.3 Beacon Pharma Kidney Cancer Medicine Introduction

11.16.4 Beacon Pharma Revenue in Kidney Cancer Medicine Business (2020-2025)

11.16.5 Beacon Pharma Recent Development

11.17 SAMARTH

11.17.1 SAMARTH Company Details

11.17.2 SAMARTH Business Overview

11.17.3 SAMARTH Kidney Cancer Medicine Introduction

11.17.4 SAMARTH Revenue in Kidney Cancer Medicine Business (2020-2025)

11.17.5 SAMARTH Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Pfizer Inc

Bristol–Myers Squibb

Roche

GSK

Novartis

Bayer

Merck

Exelixis Inc

Takeda

Eisai Co Ltd

CTTQ

AVEO Oncology

Everest Pharm

Cipla Ltd

NATco

Beacon Pharma

SAMARTH

List of Tables

Table 1. Global Kidney Cancer Medicine Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Monoclonal Antibody

Table 3. Key Players of mTOR Inhibitors

Table 4. Key Players of Kinase Inhibitors

Table 5. Key Players of Other

Table 6. Global Kidney Cancer Medicine Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Kidney Cancer Medicine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Kidney Cancer Medicine Market Size by Region (2020-2025) & (US$ Million)

Table 9. Global Kidney Cancer Medicine Market Share by Region (2020-2025)

Table 10. Global Kidney Cancer Medicine Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 11. Global Kidney Cancer Medicine Market Share by Region (2026-2031)

Table 12. Kidney Cancer Medicine Market Trends

Table 13. Kidney Cancer Medicine Market Drivers

Table 14. Kidney Cancer Medicine Market Challenges

Table 15. Kidney Cancer Medicine Market Restraints

Table 16. Global Kidney Cancer Medicine Revenue by Players (2020-2025) & (US$ Million)

Table 17. Global Kidney Cancer Medicine Market Share by Players (2020-2025)

Table 18. Global Top Kidney Cancer Medicine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Medicine as of 2024)

Table 19. Ranking of Global Top Kidney Cancer Medicine Companies by Revenue (US$ Million) in 2024

Table 20. Global 5 Largest Players Market Share by Kidney Cancer Medicine Revenue (CR5 and HHI) & (2020-2025)

Table 21. Global Key Players of Kidney Cancer Medicine, Headquarters and Area Served

Table 22. Global Key Players of Kidney Cancer Medicine, Product and Application

Table 23. Global Key Players of Kidney Cancer Medicine, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Kidney Cancer Medicine Market Size by Type (2020-2025) & (US$ Million)

Table 26. Global Kidney Cancer Medicine Revenue Market Share by Type (2020-2025)

Table 27. Global Kidney Cancer Medicine Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 28. Global Kidney Cancer Medicine Revenue Market Share by Type (2026-2031)

Table 29. Global Kidney Cancer Medicine Market Size by Application (2020-2025) & (US$ Million)

Table 30. Global Kidney Cancer Medicine Revenue Market Share by Application (2020-2025)

Table 31. Global Kidney Cancer Medicine Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 32. Global Kidney Cancer Medicine Revenue Market Share by Application (2026-2031)

Table 33. North America Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 34. North America Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)

Table 35. North America Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)

Table 36. Europe Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 37. Europe Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)

Table 38. Europe Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)

Table 39. Asia-Pacific Kidney Cancer Medicine Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 40. Asia-Pacific Kidney Cancer Medicine Market Size by Region (2020-2025) & (US$ Million)

Table 41. Asia-Pacific Kidney Cancer Medicine Market Size by Region (2026-2031) & (US$ Million)

Table 42. Latin America Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Latin America Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)

Table 44. Latin America Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)

Table 45. Middle East & Africa Kidney Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 46. Middle East & Africa Kidney Cancer Medicine Market Size by Country (2020-2025) & (US$ Million)

Table 47. Middle East & Africa Kidney Cancer Medicine Market Size by Country (2026-2031) & (US$ Million)

Table 48. Pfizer Company Details

Table 49. Pfizer Business Overview

Table 50. Pfizer Kidney Cancer Medicine Product

Table 51. Pfizer Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 52. Pfizer Recent Development

Table 53. Bristol-Myers Squibb Company Details

Table 54. Bristol-Myers Squibb Business Overview

Table 55. Bristol-Myers Squibb Kidney Cancer Medicine Product

Table 56. Bristol-Myers Squibb Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 57. Bristol-Myers Squibb Recent Development

Table 58. Roche Company Details

Table 59. Roche Business Overview

Table 60. Roche Kidney Cancer Medicine Product

Table 61. Roche Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 62. Roche Recent Development

Table 63. GSK Company Details

Table 64. GSK Business Overview

Table 65. GSK Kidney Cancer Medicine Product

Table 66. GSK Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 67. GSK Recent Development

Table 68. Novartis Company Details

Table 69. Novartis Business Overview

Table 70. Novartis Kidney Cancer Medicine Product

Table 71. Novartis Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 72. Novartis Recent Development

Table 73. Bayer Company Details

Table 74. Bayer Business Overview

Table 75. Bayer Kidney Cancer Medicine Product

Table 76. Bayer Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 77. Bayer Recent Development

Table 78. Merck & Co. Company Details

Table 79. Merck & Co. Business Overview

Table 80. Merck & Co. Kidney Cancer Medicine Product

Table 81. Merck & Co. Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 82. Merck & Co. Recent Development

Table 83. Exelixis Company Details

Table 84. Exelixis Business Overview

Table 85. Exelixis Kidney Cancer Medicine Product

Table 86. Exelixis Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 87. Exelixis Recent Development

Table 88. Takeda Company Details

Table 89. Takeda Business Overview

Table 90. Takeda Kidney Cancer Medicine Product

Table 91. Takeda Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 92. Takeda Recent Development

Table 93. Eisai Company Details

Table 94. Eisai Business Overview

Table 95. Eisai Kidney Cancer Medicine Product

Table 96. Eisai Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 97. Eisai Recent Development

Table 98. CTTQ Company Details

Table 99. CTTQ Business Overview

Table 100. CTTQ Kidney Cancer Medicine Product

Table 101. CTTQ Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 102. CTTQ Recent Development

Table 103. AVEO Oncology Company Details

Table 104. AVEO Oncology Business Overview

Table 105. AVEO Oncology Kidney Cancer Medicine Product

Table 106. AVEO Oncology Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 107. AVEO Oncology Recent Development

Table 108. Everest Pharm Company Details

Table 109. Everest Pharm Business Overview

Table 110. Everest Pharm Kidney Cancer Medicine Product

Table 111. Everest Pharm Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 112. Everest Pharm Recent Development

Table 113. Cipla Company Details

Table 114. Cipla Business Overview

Table 115. Cipla Kidney Cancer Medicine Product

Table 116. Cipla Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 117. Cipla Recent Development

Table 118. NATCO Company Details

Table 119. NATCO Business Overview

Table 120. NATCO Kidney Cancer Medicine Product

Table 121. NATCO Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 122. NATCO Recent Development

Table 123. Beacon Pharma Company Details

Table 124. Beacon Pharma Business Overview

Table 125. Beacon Pharma Kidney Cancer Medicine Product

Table 126. Beacon Pharma Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 127. Beacon Pharma Recent Development

Table 128. SAMARTH Company Details

Table 129. SAMARTH Business Overview

Table 130. SAMARTH Kidney Cancer Medicine Product

Table 131. SAMARTH Revenue in Kidney Cancer Medicine Business (2020-2025) & (US$ Million)

Table 132. SAMARTH Recent Development

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Kidney Cancer Medicine Picture

Figure 2. Global Kidney Cancer Medicine Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Kidney Cancer Medicine Market Share by Type: 2024 VS 2031

Figure 4. Monoclonal Antibody Features

Figure 5. mTOR Inhibitors Features

Figure 6. Kinase Inhibitors Features

Figure 7. Other Features

Figure 8. Global Kidney Cancer Medicine Market Size by Application (2020-2031) & (US$ Million)

Figure 9. Global Kidney Cancer Medicine Market Share by Application: 2024 VS 2031

Figure 10. Renal Cell Carcinoma (RCC) Case Studies

Figure 11. Transitional Cell Carcinoma (TCC) Case Studies

Figure 12. Kidney Cancer Medicine Report Years Considered

Figure 13. Global Kidney Cancer Medicine Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Kidney Cancer Medicine Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Kidney Cancer Medicine Market Share by Region: 2024 VS 2031

Figure 16. Global Kidney Cancer Medicine Market Share by Players in 2024

Figure 17. Global Top Kidney Cancer Medicine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Medicine as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Kidney Cancer Medicine Revenue in 2024

Figure 19. North America Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Kidney Cancer Medicine Market Share by Country (2020-2031)

Figure 21. United States Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Kidney Cancer Medicine Market Share by Country (2020-2031)

Figure 25. Germany Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Kidney Cancer Medicine Market Share by Region (2020-2031)

Figure 33. China Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Kidney Cancer Medicine Market Share by Country (2020-2031)

Figure 41. Mexico Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Kidney Cancer Medicine Market Share by Country (2020-2031)

Figure 45. Turkey Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Kidney Cancer Medicine Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Pfizer Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 50. Roche Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 51. GSK Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 52. Novartis Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 53. Bayer Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 54. Merck & Co. Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 55. Exelixis Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 56. Takeda Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 57. Eisai Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 58. CTTQ Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 59. AVEO Oncology Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 60. Everest Pharm Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 61. Cipla Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 62. NATCO Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 63. Beacon Pharma Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 64. SAMARTH Revenue Growth Rate in Kidney Cancer Medicine Business (2020-2025)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Kidney Cancer Drugs Market Research Report 2024

Global Kidney Cancer and Renal Cell Carcinoma RCC Drugs Market Insights Forecast to 2030

Global Kidney Cancer Therapeutics Market Research Report 2025

Global Kidney Cancer or Renal Cancer Market Research Report 2024

Renal Cell Carcinoma Therapy Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Kidney Cancer Market Research Report 2025

Global Kidney Cancer Therapy Market Research Report 2024

Global Kidney Cancer Therapeutics and Diagnostics Market Insights Forecast to 2030

Kidney Cancer Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Urothelial Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cancer Drug Therapy Market Insights Forecast to 2030

Global Urological Cancer Therapeutics Drugs Market Research Report 2024

Global Renal Cell Cacinoma Drugs Market Research Report 2024

Advanced Renal Cell Carcinoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Renal Diseases Drug Market Insights Forecast to 2030

Global Renal Therapeutic Market Research Report 2025

Global Kidney Cancer Molecular Diagnostics Market Research Report 2024

Global Kidney Cancer Targeted Therapy Market Research Report 2025

Sorafenib Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions